AnPac Bio rises on U.S. patent for medical devices
** Shares of biotech co ANPC.O up 12.4% at $65 premarket
** Co says it has been granted a U.S. patent for its medical
devices for both disease detection and treatment applications
** The patent covers device structures and methods to modify
biological samples for treatment purposes
** Co says its newly launched cancer treatment joint venture
has secured over $4 million of capital contributions from
multiple funding sources urn:newsml:reuters.com:*:nGNXb3PpmK
** Co said in May it would form a JV with its founder and
chairman, Dr. Chris Chang Yu, for cancer treatment research
** Up to Thursday's close, stock had fallen ~18% this year
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022